Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Immunophotonics, Inc. logo — Interventional Immuno-Oncology

Immunophotonics, Inc.

Interventional Immuno-Oncology

Founded 2012 United States St. Louis, United States 17 employees Series Unknown Total: $31.87M Biotechnology, Health Care +1

General Information

Company Name Immunophotonics, Inc.
Founded Year 2012
Location United States St. Louis, United States +2
Founders / Decision Makers
Team member
Employees 17
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series Unknown
Social

Get notified when Immunophotonics, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Immunophotonics, Inc.

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• - 29 Feb 2024
Venture Round •••••• - 14 Feb 2023
Series B •••••• 4
Investor Investor
•••• •••• 		06 Apr 2022
Grant •••••• 1 •••• •••• 17 Feb 2022
Venture Round •••••• 1
Investor
01 Jun 2018

View All 10 Funding Rounds

Immunophotonics, Inc. Alternatives & Competitors

Immunophotonics, Inc. vs
Red Arrow Therapeutics
Red Arrow Therapeutics United States

Transforming powerful biology into safe therapies through pH-responsive nanotechnology

Seed
8 employees
Biotechnology
Immunophotonics, Inc. vs
Lytix Biopharma
Lytix Biopharma Norway

A clinical-stage immuno-oncology company developing proprietary oncolytic drugs as a novel therapy t...

Grant
15 employees
Biotechnology, Health Care
Immunophotonics, Inc. vs
PDX Pharmaceuticals
PDX Pharmaceuticals United States

Delivery of Next-Gen Combination and Immunotherapies on Nanotechnology Platform.

Series A
9 employees
Biotechnology, Health Care

FAQ About Immunophotonics, Inc.

Interventional Immuno-Oncology
Immunophotonics, Inc. was founded in 2012.
Immunophotonics, Inc. is headquartered in St. Louis, United States.
Immunophotonics, Inc. operates in the following industries: Biotechnology, Health Care, Life Sciences.
Immunophotonics, Inc. has approximately 17 employees.
Immunophotonics, Inc. has completed 10 funding rounds, raising a total of $31.87M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Immunophotonics, Inc. include Red Arrow Therapeutics, Lytix Biopharma, PDX Pharmaceuticals, Gritstone bio, Batu Biologics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immunophotonics, Inc. and Red Arrow Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Immunophotonics, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes